December 3, 2014 Conference Highlights Public Private Partnership Role in Medical Product Development December 3, 2014 | Download PDF Conference Highlights Public Private Partnership Role in Medical Product Development Global
January 7, 2014 Coalition Against Major Diseases/European Medicines Agency Biomarker Qualification Of Hippocampal Volume For Enrichment Of Clinical Trials In Predementia Stages Of Alzheimer’s Disease
April 29, 2014-April 30, 2014 Fifth Annual Patient-Reported Outcome (PRO) Consortium Workshop Honoring the Past, Navigating the Present, Charting the Future April 29 – 30, 2014 Sheraton Silver Spring Hotel 8777 Georgia Ave
July 10, 2013 U.S. Food and Drug Administration and European Medicines Agency Reach Landmark Decisions on Critical Path Institute’s Clinical Trial Simulation Tool for Alzheimer’s Disease
May 24, 2013 Leading US and European Medical Public-Private Partnerships Announce Agreement The Predictive Safety Testing Consortium (PSTC) led by the Critical Path Institute (C-Path) and the Safer and Faster Evidence-base
August 28, 2012 Towards Consensus Development: Qualifying Endpoint Measures for Rheumatoid Arthritis Clinical Trails August 28, 2012 Sheraton Silver Spring Hotel 8777 Georgia Avenue – Silver Spring, MD 20910 SPONSORED BY: Critical Path Insti
April 4, 2012 Third Annual Patient-Reported Outcome Consortium Workshop April 4, 2012 Sheraton Silver Spring Hotel 8777 Georgia Avenue – Silver Spring, MD 20910 SPONSORED BY: Critical Path Institu
January 24, 2012 European Medicines Agency Deems Imaging Biomarker a Qualified Measure to Select Patients with Early Stages of Cognitive Impairment for Alzheimer’s Disease Clinical Trials Based on a request for regulatory review by Critical Path Institute’s (C-Path) Coalition Against Major Diseases (CAMD), the
March 23, 2010 First Annual Patient-Reported Outcome Consortium Workshop March 23, 2010 Sheraton Silver Spring Hotel 8777 Georgia Avenue – Silver Spring, MD 20910 SPONSORED BY: Critical Path Instit
October 5, 2010 Renal Biomarker Qualification Submission: A Dialog Between the FDA-EMEA and Predictive Safety Testing Consortium
